The outcomes of genome-wide association studies (GWAS) have not been what scientists expected, but researchers are developing new approaches to use revelatory GWAS information to identify genetic causal variants, predictors of treatment response, and future opportunities for genetic insight.
Letter: RA Approval for IL-1Ra
Investors convinced the executives of Synergen that they needed to evaluate IL-1Ra for a disease with a more rapid outcome. RA studies were too slow to yield a quick profit. Thus, they picked sepsis syndrome.
Data-Driven, Optimal Patient Care and Clinical Research
Expanded opportunities to advance rheumatology will be offered by ACR’s ongoing registry efforts
A Short History of Rheumatoid Arthritis Therapeutics
Or, why I chose to become a rheumatologist
Dos and Don’ts of Verifying Insurance Benefits
Not verifying insurance benefits prior to rendering service can result in nonpayment, which affects your bottom line. Because this is a costly mistake that can be avoided, make it routine to verify eligibility prior to every patient visit.
Health Policy Outlook for 2012
What’s in Store for Rheumatology in 2012?
Coding Corner Question: Eligibility Quiz for Front Office Staff
January’s Coding Challenge
Coding Corner Answer: Eligibility Quiz for Front Office Staff
January’s Coding Answer
Incoming ARHP Volunteers
Laurie Hughell, PA- C, MPH and Susan Richmond, MS, PA-C
Opening a New Therapeutic Window for Rheumatoid Arthritis
New targets in rheumatoid arthritis: SYK, JAK, BTK